Potential impact of a new pandemic could be catastrophic.
If a pandemic as deadly as the 1918 Spanish Flu Pandemic were to strike today, potentially 33 million are predicted to die within six months*, and if the outbreak lasts as long, it is reasonable to project that 100 million people could die in 18 months. The threat of another pandemic as devastating as the 1918 flu is very real.
“Given the continual emergence of new pathogens, the increasing risk of a bioterror attack, and how connected our world is through air travel, there is a significant probability of a large and lethal, modern-day pandemic occurring in our lifetimes.” – Bill Gates
LexaGene’s open-access instrument can be rapidly configured to detect novel pathogens for use in preventing a pandemic.
LexaGene’s open-access diagnostic instrument is ideally suited for preventing such a catastrophe, whether it is caused by influenza, coronavirus, or any other pathogen. In the event of another pandemic, the best way to minimize deaths is to quickly place infected individuals into quarantine. However, such decisions are more easily made if rapid and accurate diagnostics are available at the point-of-need to conclusively determine whether quarantine is required.
Fortunately, facilities with LexaGene’s open-access technology in place will be able to accurately detect not only common pathogens but also a novel pathogen within a week of its genome being sequenced. This is because LexaGene’s technology uses standard liquid reagents (20X qPCR) that can be quickly generated by numerous manufacturers and shipped overnight. These manufacturers can generate sufficient reagents to provide worldwide coverage within a weeks’ time.
This speed is in stark contrast to competitor point-of-care technologies that have reagents pre-embedded into complex and expensive cartridges that are only manufactured by a single production site – making it impossible to rapidly meet a rise in demand. The lack of technologies like LexaGene’s puts us at risk of leaving our physicians and nurses without the diagnostic tests required to make critical point-of-care decisions regarding quarantine.
LexaGene’s open-access technology will rapidly return results to improve quarantine decision making and help minimize the spread of disease that could lead to a pandemic.
Read news on LexaGene’s ability to detect pathogens like coronavirus rapidly, onsite at point-of-need.